Nigeria Secures €50 Million Investment to Strengthen Pharmaceutical Manufacturing

Nigeria’s pharmaceutical and healthcare sector is set for significant growth following a €50 million financing agreement between the Bank of Industry (BOI) and the European Investment Bank (EIB).

The funding will be channelled into local pharmaceutical, vaccine, and diagnostic manufacturing, with a focus on expanding production capacity and reducing reliance on imports. This move is expected to strengthen Nigeria’s position within the regional healthcare supply chain while improving long-term industry sustainability.

A key objective of the investment is to improve access to financing for small and medium-sized enterprises operating within the healthcare value chain. With greater financial support, these businesses will be better positioned to scale operations, meet international quality standards, and compete more effectively across both regional and global markets.

For distributors, importers, and buyers across West Africa, this development signals a shift towards increased local availability of high-quality, cost-effective medicines. Strengthening domestic production will also help improve supply chain resilience and reduce vulnerability to global disruptions.

The initiative aligns with wider efforts across Africa to boost local pharmaceutical production, enhance healthcare security, and reduce dependence on imported medical products.

As investment in Nigeria’s healthcare infrastructure continues to grow, new opportunities are emerging across the pharmaceutical value chain, from manufacturing and distribution to strategic partnerships and procurement.